Vivos Therapeutics, Inc.
VVOS · XNASCIK 1716166fmd_197JYBBD0KG725G71A8SDHPJJMManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2026, 27 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 11 | 13 | 17 | 16 | 14 | 15 | 17 |
| Cost of revenue | – | 0 | 0 | 0 | 6 | 6 | 7 |
| Gross profit | 9 | 10 | 13 | 10 | 8 | 9 | 11 |
| Research and development | – | – | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 18 | 18 | 31 | 34 | 25 | 20 | 29 |
| Total operating expenses | 19 | 22 | 33 | 35 | 26 | 20 | 30 |
| Operating income | (11) | (12) | (20) | (25) | (17) | (11) | (20) |
| Interest expense | 0 | 0 | 0 | – | – | – | 1 |
| Interest and investment income | – | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | (0) | (0) | (0) | (0) | (1) |
| Income before taxes | (11) | (12) | (20) | (24) | (14) | (11) | (21) |
| Net income | (11) | (12) | (20) | (24) | (14) | (11) | (21) |
| Net income to common shareholders | (12) | (18) | (20) | (24) | (14) | (11) | (21) |